Live attenuated intranasal influenza vaccine

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 1, 2012, Pages 76-80

  Esposito, Susanna ^a   Montinaro, Valentina ^a   Groppali, Elena ^a   Tenconi, Rossana ^a   Semino, Margherita ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Children; Influenza; Influenza vaccination; Influenza vaccines; Pediatrics

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; PLACEBO; IMMUNOGLOBULIN A; TRIPLE VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ASTHMA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; NOSE CONGESTION; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RHINORRHEA; SEROCONVERSION; SORE THROAT; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; WHEEZING; ACUTE OTITIS MEDIA; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE EXACERBATION; DRUG USE; FEVER; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS B;

EID: 84861800171     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.1.18809     Document Type: Review

References (42)

1. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1128-32; PMID: 21866086
2. Loerbroks A, Stock C, Bosch JA, Litaker DG, Apfelbacher CJ. Influenza vaccination coverage among high-risk groups in 11 European countries. Eur J Public Health 2011; PMID:21750011; http://dx.doi.org/10. 1093/eurpub/ckr094
3. Paget WJ, Balderston C, Casas I, Donker G, Edelman L, Fleming D, et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr 2010; 169:997- 1008; PMID:20229049; http://dx.doi.org/10.1007/ s00431-010-1164-0
4. Esposito S, Daleno C, Baldanti F, Scala A, Campanini G, Taroni F, et al. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virol J 2011; 8:349; PMID:21752272; http://dx.doi.org/10. 1186/1743-422X-8-349
5. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7:CD001269; PMID:20614424
6. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 2: CD004879; PMID:18425905
7. Esposito S, Principi N. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. Vaccine 2011; 29:7535-41; PMID: 21820478; http://dx.doi.org/10.1016/j.vaccine.2011. 08.012
8. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007; 25:5367-73; PMID:17559990; http://dx.doi.org/10.1016/j.vaccine. 2007.05.002
9. Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29:8788-801; PMID:21968444; http://dx.doi.org/10.1016/j.vaccine. 2011.09.077
10. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008; 2:193-202; PMID:19453395; http://dx.doi.org/10.1111/j.1750-2659.2008.00056.x
11. WHO. Global pandemic influenza action plan to increase vaccine supply: progress report 2008 (WHO/ IVB/09/05) [online]. Available from URL: http:// whqlibdoc.who.int/hq/2009/WHO-IVB-09.05-eng.pdf Accessed March 14, 2011.
12. Buonagurio DA, Bechert TM, Yang C-F, Shutyak L, D'Arco GA, Kazachkov Y, et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 2006; 24:2151-60; PMID:16413951; http://dx.doi.org/10.1016/j.vaccine.2005.11.007
13. European Medicine Agency. Fluenz Influenza Vaccine. Authorization Details http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/ 001101/human-med-001405.jsp&mid=WC0b01ac 058001d125&murl=menus/ medicines/medicines.jsp& jsenabled=true. Accessed October 24, 2011.
14. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338: 1405-12; PMID:9580647; http://dx.doi.org/10.1056/ NEJM199805143382002
15. Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009; 28:365-71; PMID:19395948; http://dx.doi.org/ 10.1097/INF.0b013e31819219b8
16. Tam JS, Capeding MRZ, Lum LCS, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007; 26:619-28; PMID:17596805; http://dx.doi.org/10. 1097/INF.0b013e31806166f8
17. Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Cold-Adapted, Trivalent, Influenza Vaccine Study Group. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003; 22:28-34; PMID:12544405; http:// dx.doi.org/10.1097/00006454-200301000-00010
18. Boyce TG, Gruber WC, Coleman-Dockery SD, Sannella EC, Reed GW, Wolff M, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999; 18:82-8; PMID:10501238; http://dx.doi.org/ 10.1016/S0264-410X(99)00183-8
19. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz(TM)): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011; 71:1591-622; PMID:21861544; http://dx.doi.org/10.2165/11206860-000000000-00000
20. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-53; PMID: 18448618; http://dx.doi.org/10.1128/CVI.00397-07
21. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, coldadapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18:899-906; PMID:10580204; http://dx.doi.org/10. 1016/S0264-410X(99)00334-5
22. He X-S, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80:11756- 66; PMID:16971435; http://dx.doi.org/10.1128/JVI. 01460-06
23. Belshe RB, Gruber W, Mendelman P, Cho I, Reisinger K, Block S, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168-75; PMID: 10657821; http://dx.doi.org/10. 1016/S0022-3476(00) 70097-7
24. Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006; 118:2298-312; PMID:17142512; http://dx.doi. org/10.1542/peds.2006-0725
25. Lum LCS, Forrest BD. the LAIV Concomitant Vaccine Study Group. Safety, efficacy, and immunogenicity of live attenuated influenza vaccine concurrently administered with a combination ofmumps, measles, and rubella vaccine. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 13-16, 2008; Graz, Austria.
26. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith D, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9; PMID:17006279; http://dx.doi.org/ 10.1097/01.inf.0000237829.66310.85
27. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9; PMID:17006278; http://dx.doi.org/10.1097/01.inf. 0000237797.14283.cf
28. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96; PMID:17301299; http://dx.doi.org/10. 1056/NEJMoa065368
29. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009; 27:1101-10; PMID:19095024; http://dx.doi.org/10. 1016/j.vaccine.2008.11.093
30. Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-7; PMID:18597900; http://dx.doi.org/10.1016/j.vaccine.2008.05.054
31. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149-56; PMID:20003926; http://dx.doi.org/10.1016/j.vaccine.2009.11.068
32. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137-44; PMID:10411194; http://dx.doi. org/10.1001/jama.282.2.137
33. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7; PMID:19776407; http://dx.doi. org/10.1056/ NEJMoa0808652
34. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7; PMID:10720541; http://dx.doi. org/10.1086/315323
35. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, et al. A randomized, doubleblind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590-5; PMID:16804427; http://dx.doi.org/10.1097/ 01.inf. 0000220229.51531.47
36. MedImmune LLC. FluMist- intranasal live influenza vaccine, 2010-2011 formula: US prescribing information [online]. Available from URL: http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/Approved Products/ucm123743.pdf. Accessed Sep 20, 2010.
37. Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23:138-44; PMID:14872180; http://dx.doi.org/10.1097/01.inf. 0000109392.96411.4f
38. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respi Viruses 2011; 5:389-97; PMID:21668683; http://dx.doi.org/10.1111/j.1750-2659.2011.00243.x
39. Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011; 204:1475- 82; PMID:21949042; http://dx.doi.org/10.1093/ infdis/jir561
40. King JC, Jr., Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)- infected and non-HIV-infected adults. J Infect Dis 2000; 181:725-8; PMID:10669363; http://dx.doi.org/ 10.1086/315246
41. Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, et al. Safety and tolerability of coldadapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002; 21:44-8; PMID:11791098; http://dx.doi.org/10.1097/ 00006454-200201000-00010
42. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 2008; 27:444-52; PMID:18401289; http://dx.doi.org/10.1097/INF. 0b013e3181660c2e